Robert W. Holloway, MD
Medical Director (Gyn Onc), Gynecologic Oncologist
Cancer

Overview
Dr. Robert W. Holloway, MD is a board-certified gynecology oncologist in Orlando. Dr. Holloway joined the Florida Hospital Cancer Institute in 1994, and serves as the medical director of the Gynecologic Oncology Program. A graduate of Vanderbilt University School of Medicine, Dr. Holloway completed his OB/GYN residency at the University of Alabama at Birmingham and his fellowship in gynecologic oncology at Georgetown University in Washington, DC. Dr. Holloway is a Fellow of the American College of Surgeons. Additionally, Dr. Holloway is the principal investigator for several clinical trials and lectures regularly both nationally and internationally. His major research interests are robotic surgery and novel ovarian cancer therapies. Surgeons from around the world routinely attend his advanced training programs in robotic surgery.
Articles
Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
Gynecologic oncology
2022
Multidisciplinary approach to pelvic leiomyomatosis with intracaval and intracardiac extension: A case report and review of the literature
GYNECOLOGIC ONCOLOGY REPORTS
2022
The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
CANCER MEDICINE
2021
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives
GYNECOLOGIC ONCOLOGY
2021
Intratubal Pseudopapillary Histiocytic Hyperplasia: A New Histologic Variant in the Spectrum of Histiocytic Lesions Involving the Fallopian Tube
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2021
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
GYNECOLOGIC ONCOLOGY
2021
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer
Gynecologic oncology
2021
Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types
JOURNAL OF MOLECULAR DIAGNOSTICS
2021
Education & Training
Education
Vanderbilt University Medical Center
Residency
University of Alabama Birmingham
Fellowship
Georgetown University Hospital
Specialty
Gynecology Oncology
Board Certifications
American Board of Obstetrics & Gynecology